WO2004016256A3 - Agonisme du recepteur 5ht2a pour le traitement du dysfonctionnement de la thermoregulation - Google Patents

Agonisme du recepteur 5ht2a pour le traitement du dysfonctionnement de la thermoregulation Download PDF

Info

Publication number
WO2004016256A3
WO2004016256A3 PCT/US2003/025650 US0325650W WO2004016256A3 WO 2004016256 A3 WO2004016256 A3 WO 2004016256A3 US 0325650 W US0325650 W US 0325650W WO 2004016256 A3 WO2004016256 A3 WO 2004016256A3
Authority
WO
WIPO (PCT)
Prior art keywords
agonism
treatment
5ht2a receptor
thermoregulatory dysfunction
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/025650
Other languages
English (en)
Other versions
WO2004016256A2 (fr
Inventor
Darlene Coleman Deecher
Istvan Jozsef Merchenthaler
Liza Leventhal
Kimberly Jean Sipe
Lawrence Thomas O'connor
Terrance Harold Andree
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UAA200500883A priority Critical patent/UA81423C2/xx
Priority to EP03788552A priority patent/EP1534258A2/fr
Priority to MXPA05001803A priority patent/MXPA05001803A/es
Priority to BR0313624-8A priority patent/BR0313624A/pt
Priority to CA002494687A priority patent/CA2494687A1/fr
Priority to AU2003256430A priority patent/AU2003256430A1/en
Priority to JP2004529482A priority patent/JP2006500366A/ja
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of WO2004016256A2 publication Critical patent/WO2004016256A2/fr
Publication of WO2004016256A3 publication Critical patent/WO2004016256A3/fr
Priority to IL16658605A priority patent/IL166586A0/xx
Anticipated expiration legal-status Critical
Priority to NO20051304A priority patent/NO20051304L/no
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne une méthode de traitement de troubles de la thermorégulation consistant à administrer des composés et des compositions de composés qui, en modulant les niveaux de 5HT, activent le récepteur 5HT2a. Cette invention porte également sur un traitement faisant intervenir des antagonistes du récepteur 5HT1a combinés à des inhibiteurs de recaptage de la sérotonine (SRI) ainsi que sur des compositions pharmaceutiques et des produits contenant cette combinaison.
PCT/US2003/025650 2002-08-15 2003-08-14 Agonisme du recepteur 5ht2a pour le traitement du dysfonctionnement de la thermoregulation Ceased WO2004016256A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP03788552A EP1534258A2 (fr) 2002-08-15 2003-08-14 AGONISME DU RECEPTEUR 5HT 2a POUR LE TRAITEMENT DU DYSFONCTIONNEMENT DE LA THERMOREGULATION
MXPA05001803A MXPA05001803A (es) 2002-08-15 2003-08-14 Agonismo del receptor de 5ht2a para el tratamiento de disfuncion termorreguladora.
BR0313624-8A BR0313624A (pt) 2002-08-15 2003-08-14 Agonismo do receptor 5ht2a para tratamento da disfunção termo-regulatória
CA002494687A CA2494687A1 (fr) 2002-08-15 2003-08-14 Agonisme du recepteur 5ht<sb>2a</sb> pour le traitement du dysfonctionnement de la thermoregulation
AU2003256430A AU2003256430A1 (en) 2002-08-15 2003-08-14 AGONISM OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION
UAA200500883A UA81423C2 (en) 2002-08-15 2003-08-14 PRODUCT CONTAINING SRI AND AGONIST OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION
JP2004529482A JP2006500366A (ja) 2002-08-15 2003-08-14 温度調節機能障害の治療ための５ＨＴ２ａ受容体の拮抗
IL16658605A IL166586A0 (en) 2002-08-15 2005-01-31 Agonism of the 5ht2a receptor for treatment of thermoregulatory dysfunction
NO20051304A NO20051304L (no) 2002-08-15 2005-03-14 Agonisme av 5HT2a reseptoren for behandling av termoregulatorisk dysfunksjon

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40369202P 2002-08-15 2002-08-15
US60/403,692 2002-08-15

Publications (2)

Publication Number Publication Date
WO2004016256A2 WO2004016256A2 (fr) 2004-02-26
WO2004016256A3 true WO2004016256A3 (fr) 2004-06-17

Family

ID=31888268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/025650 Ceased WO2004016256A2 (fr) 2002-08-15 2003-08-14 Agonisme du recepteur 5ht2a pour le traitement du dysfonctionnement de la thermoregulation

Country Status (18)

Country Link
US (1) US20040063721A1 (fr)
EP (1) EP1534258A2 (fr)
JP (1) JP2006500366A (fr)
KR (1) KR20050040921A (fr)
CN (2) CN101099734A (fr)
AU (1) AU2003256430A1 (fr)
BR (1) BR0313624A (fr)
CA (1) CA2494687A1 (fr)
CO (1) CO5690568A2 (fr)
EC (1) ECSP055599A (fr)
GE (1) GEP20074192B (fr)
IL (1) IL166586A0 (fr)
MX (1) MXPA05001803A (fr)
NO (1) NO20051304L (fr)
RU (2) RU2340333C2 (fr)
UA (1) UA81423C2 (fr)
WO (1) WO2004016256A2 (fr)
ZA (1) ZA200501308B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
DE102004026670A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026669A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
DE102004026679A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
DE102005034498A1 (de) * 2005-07-20 2007-01-25 Grünenthal GmbH Orale Kontrazeption mit Trimegeston
WO2007142810A2 (fr) * 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Procédés d'utilisation de doxépine faiblement dosée pour améliorer le sommeil
WO2007136741A2 (fr) * 2006-05-19 2007-11-29 Somaxon Pharmaceuticals, Inc. N-desméthyldoxépine et procédés pour traiter les troubles du sommeil l'utilisant
US20100179214A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20100179215A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20080058408A1 (en) 2006-05-19 2008-03-06 Rogowski Roberta L Low-dose doxepin for treatment of sleep disorders in elderly patients
WO2007146073A2 (fr) * 2006-06-09 2007-12-21 Wyeth Procédé destiné à renforcer la fonction cognitive
CA2693992C (fr) 2006-07-20 2017-01-31 Somaxon Pharmaceuticals, Inc. Methodes destinees a ameliorer la pharmacocinetique de la doxepine
US20080182890A1 (en) * 2006-10-04 2008-07-31 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
WO2008052139A2 (fr) 2006-10-25 2008-05-02 Somaxon Pharmaceuticals, Inc. Doxepine à dose ultrafaible, et ses procédés d'utilisation pour traiter des troubles du sommeil
WO2008060397A2 (fr) * 2006-11-03 2008-05-22 Noven Therapeutics, Llc Procédé de traitement d'un dysfonctionnement de la thermorégulation
WO2008070795A2 (fr) * 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Polythérapie utilisant de la doxépine à faible dose pour l'amélioration du sommeil
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
CA2721133C (fr) 2007-04-13 2018-11-06 Somaxon Pharmaceuticals, Inc. Formulations de doxepine a faible dose et procede de preparation et d'utilisation de celle-ci
WO2009137531A2 (fr) * 2008-05-06 2009-11-12 Somaxon Pharmaceuticals, Inc. Compositions et procédés se rapportant à l'action de faibles dosages de doxépine sur les récepteurs h1 et 5-ht2a
EP2510949A4 (fr) 2009-12-11 2013-11-13 Astellas Pharma Inc Agent thérapeutique pour la fibromyalgie
WO2011109367A2 (fr) * 2010-03-02 2011-09-09 Royster Jr George E Procédés et compositions pour traiter ou prévenir les symptômes de changements hormonaux
US20250295611A1 (en) * 2022-04-27 2025-09-25 Tessellate Therapeutics Inc. Methods of treating 5ht2a receptor-mediated conditions
WO2025008804A1 (fr) * 2023-07-06 2025-01-09 M – Path Biopharma Ltd. Polythérapie pour apporter des améliorations aux effets secondaires d'un traitement par inhibiteurs des récepteurs des œstrogènes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0714663A2 (fr) * 1994-11-28 1996-06-05 Eli Lilly And Company Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
US5962514A (en) * 1995-04-27 1999-10-05 Astra Aktiebolag Combination of 5-HT uptake inhibitor with a selective 5-HT1A antagonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904127D0 (sv) * 1989-12-07 1989-12-07 Astra Ab New biocyclic amino-substituted compounds
US6004980A (en) * 1990-06-01 1999-12-21 Merrell Pharmaceuticals, Inc. (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
CA2083698C (fr) * 1990-06-01 1997-11-04 Albert A. Carr (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US5131149A (en) * 1991-06-19 1992-07-21 Lynn C. Thompson Folding knife
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
SE510305C2 (sv) * 1997-05-30 1999-05-10 Astra Ab Nytt salt
US20040180879A1 (en) * 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0714663A2 (fr) * 1994-11-28 1996-06-05 Eli Lilly And Company Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
US5962514A (en) * 1995-04-27 1999-10-05 Astra Aktiebolag Combination of 5-HT uptake inhibitor with a selective 5-HT1A antagonist
US6169098B1 (en) * 1995-04-27 2001-01-02 Astra Aktiebolag Composition and methods employing it for the treatment of 5-HT-mediated disorders
US6172105B1 (en) * 1995-04-27 2001-01-09 Astra Aktiebolag Composition and methods employing it for the treatment of 5-HT-mediated disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERENDSEN H H G: "Hot flushes and serotonin", JOURNAL OF THE BRITISH MENOPAUSE SOCIETY 2002 UNITED KINGDOM, vol. 8, no. 1, 2002, pages 30 - 34, XP009022459, ISSN: 1362-1807 *
ZEA-PONCE Y ET AL: "Pharmacokinetics and brain distribution in non human primate of R(-)[I]DOI, A 5HT2A/2C serotonin agonist", NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, US, vol. 29, no. 5, July 2002 (2002-07-01), pages 575 - 583, XP004367634, ISSN: 0969-8051 *

Also Published As

Publication number Publication date
AU2003256430A1 (en) 2004-03-03
BR0313624A (pt) 2005-06-21
WO2004016256A2 (fr) 2004-02-26
MXPA05001803A (es) 2005-08-16
RU2008123243A (ru) 2009-12-27
RU2340333C2 (ru) 2008-12-10
ECSP055599A (es) 2005-07-06
EP1534258A2 (fr) 2005-06-01
UA81423C2 (en) 2008-01-10
ZA200501308B (en) 2009-09-30
GEP20074192B (en) 2007-09-10
US20040063721A1 (en) 2004-04-01
JP2006500366A (ja) 2006-01-05
NO20051304L (no) 2005-05-06
CN101099734A (zh) 2008-01-09
IL166586A0 (en) 2006-01-15
CA2494687A1 (fr) 2004-02-26
CO5690568A2 (es) 2006-10-31
CN1674880A (zh) 2005-09-28
RU2005104815A (ru) 2005-08-27
KR20050040921A (ko) 2005-05-03

Similar Documents

Publication Publication Date Title
WO2004016256A3 (fr) Agonisme du recepteur 5ht2a pour le traitement du dysfonctionnement de la thermoregulation
WO2005107726A3 (fr) Procede pour le traitement de mal de dos
UA74419C2 (uk) Заміщені піридини та їх застосування як антагоністів рецептору метаботропного глутамату
EP1471909A4 (fr) Composition pharmaceutique et methode de traitement de troubles du systeme nerveux central
IL172582A0 (en) Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
WO2007051062A3 (fr) Dihydropyridines substituees et leurs methodes d&#39;utilisation
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
PH12012501640A1 (en) Novel compounds as opioid receptor modulators
HK1038755A1 (zh) Tweak及tweak受体对抗物和使用对抗物治疗免疫失常症
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2005048935A3 (fr) Methodes pour moduler l&#39;immunite
WO2005000216A3 (fr) Combinaison d&#39;un antagoniste du recepteur nmda et inhibiteur du recaptage de serotonine selectif pour le traitement de la depression et d&#39;autres troubles de l&#39;humeur
WO2005030188A3 (fr) Derives de phenyl-piperazine en tant que modulateurs des recepteurs muscariniques
ZA200706029B (en) Tricyclic &amp;-opioid domulators
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2004084943A8 (fr) Utilisation d&#39;antagonistes de la ghrelin ou du recepteur de la ghrelin pour traiter l&#39;inflammation intestinale
MXPA06000705A (es) Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos.
WO2005086656A3 (fr) Derives d&#39;heteroarylaminopyrazole utilises pour traiter le diabete
AU9543601A (en) Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
WO2007067511A3 (fr) Antagonistes de recepteur de prokineticine de morpholine-carboxamide
WO2004067510A8 (fr) Derives de 3,6-disubstitues azabicyclo hexane utilises en tant qu&#39;antagonistes du recepteur de muscarinique
WO2005009340A3 (fr) Procedes destines au traitement ou a la prevention de troubles respiratoires avec un inhibiteur de cyclooxygenase-2 utilise en combinaison avec un antagoniste de recepteur muscarinique et composition les contenant
TW200621767A (en) Tricyclic δ-opioid modulators
WO2004098522A3 (fr) Composes de la vitamine d3 gemini et methodes d&#39;utilisation de ces composes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 166586

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2494687

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003788552

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 538186

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/001803

Country of ref document: MX

Ref document number: 200501308

Country of ref document: ZA

Ref document number: 1020057002481

Country of ref document: KR

Ref document number: 1-2005-500309

Country of ref document: PH

Ref document number: 05013165

Country of ref document: CO

Ref document number: 182/KOLNP/2005

Country of ref document: IN

ENP Entry into the national phase

Ref country code: GE

Ref document number: GE P

WWE Wipo information: entry into national phase

Ref document number: 8633

Country of ref document: GE

Ref document number: 20050047

Country of ref document: UZ

Ref document number: 2003256430

Country of ref document: AU

Ref document number: 2004529482

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20038194775

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1200500306

Country of ref document: VN

ENP Entry into the national phase

Ref document number: 2005104815

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020057002481

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003788552

Country of ref document: EP